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Abstract
Objective: Neurosteroids regulate neuronal excitability by potentiating caminobutyric acid type-A receptors (GABARs). In animal models of temporal
lobe epilepsy, the neurosteroid sensitivity of GABARs is diminished and
GABAR subunit composition is altered. We tested whether similar changes
occur in patients with epilepsy and if depolarization-induced increases in neuronal activity can replicate this effect. Methods: We determined GABAR a4
subunit expression in cortical tissue resected from pediatric epilepsy patients.
Modulation of human GABARs by allopregnanolone and Ro15-4513 was measured in Xenopus oocytes using whole-cell patch clamp. To extend the findings
obtained using tissue from epilepsy patients, we evaluated GABAR expression
and modulation by allopregnanolone and Ro15-4513 in cultured rat hippocampal neurons exposed to high extracellular potassium (HK) to increase neuronal
activity. Results: Expression of a4 subunits was increased in pediatric cortical
epilepsy specimens encompassing multiple pathologies. The potentiation of
GABA-evoked currents by the neurosteroid allopregnanolone was decreased in
Xenopus oocytes expressing GABARs isolated from epilepsy patients. Furthermore, receptors isolated from epilepsy but not control tissue were sensitive to
potentiation by Ro15-4513, indicating higher expression of a4bxc2 subunit-containing receptors. Correspondingly, increasing the activity of cultured rat hippocampal neurons reduced allopregnanolone potentiation of miniature
inhibitory postsynaptic currents (mIPSCs), increased modulation of tonic
GABAR current by Ro15-4513, upregulated the surface expression of a4 and c2
subunits, and increased the colocalization of a4 and c2 subunit immunoreactivity. Interpretation: These findings suggest that seizure activity-induced upregulation of a4bxc2 subunit-containing GABARs could affect the anticonvulsant
actions of neurosteroids.

Introduction
Neurosteroids, the metabolites of gonadal and adrenal
steroid hormones, potentiate c-aminobutyric acid type-A
receptors (GABARs),1-3 dampen neuronal excitability, and
regulate seizure susceptibility.4-9 However, neurosteroid
sensitivity of GABARs in the dentate granule cells and
cortical pyramidal neurons of animals with epilepsy is
diminished.10-15 Subunits constituting GABARs are altered
in epilepsy models such that the d and a1 subunit

expression is reduced, whereas that of the a4 and c2 subunits is increased.13,16-18 Furthermore, a larger fraction of
synaptic GABARs contain a4 and c2 subunits.13,14 Altered
neurosteroid potentiation of GABAR-mediated inhibition
and associated increased expression of a4c2 subunit-containing receptors has not been described in tissue resected
from patients with epilepsy.
Epilepsy-associated changes in GABAR expression
could be due to the effect of increased neuronal activity
during recurrent spontaneous seizures or a consequence
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Table 1. Control brain specimens analyzed in western blotting studies.
Control number

Age

Sex

Brain region

Cause of death

PMI (hours)

1*
2*
3*
4*
5
6
7
8
9
10

8
13.3
4.8
4
7.7
12.9
1.7
2.8
17.5
20.3

M
M
F
M
M
M
M
F
M
M

Temporal
Occipital
Frontal
Frontal
Occipital
Occipital
Parietal
Parietal
Frontal
Occipital

Cardiac Arrhythmia
Asphyxia
Asthma
n/a
Drowning
Asthma
Asthma
Drowning
MVC
MVC

5
5
15
n/a
12
15
10
12
4
3

Notes

Normal cortex removed during tumor surgery

PMI, postmortem interval; MVC, motor vehicle collision.
*Specimens also used in electrophysiology studies.

of the initial epileptogenic injury. Furthermore, increased
neuronal activity and synchronization during seizures
could induce pathological changes or homeostatic alterations. Homeostatic plasticity involves scaling up of inhibitory neurotransmission following increase in neuronal
activity and vice a versa.19-23 In contrast to the pathological alterations such as cell death and kindling which
increase the likelihood of subsequent seizures, homeostatic plasticity would dampen neuronal activity and
reduce the likelihood of seizures. It remains unclear
whether the epilepsy-associated changes in GABARs constitute pathological or homeostatic alterations.14,24,25
Prior qRT-PCR and immunohistochemical studies have
revealed increased expression of a4 subunits coincident
with the onset of spontaneous seizures.18,26 Spontaneous
seizure activity also appears to transiently upregulate a4
subunit expression,27 which suggests that the plasticity of
a4 subunits could be a homeostatic response. However,
alterations in multiple cellular signaling pathways and
variability of spontaneous seizures in epileptic animals
confound these in vivo studies.
Cultured neurons provide a controlled system to study
the effect of increased neuronal activity on homeostatic
plasticity of GABARs. High extracellular potassium (HK)
increases neuronal activity in cultures,23 and these neurons have larger GABAR-mediated synaptic currents, similar to those observed in hippocampal neurons of
epileptic animals.14,28 This enhancement could be a
homeostatic response to curb increased neuronal firing as

the potentiation of GABAergic inhibition corresponds
with the stabilization of firing rate.23 However, whether
this plasticity involves upregulation of existing receptors
or de novo expression of receptors with altered neurosteroid sensitivity and distinct subunit composition is not
known.
In this study, we determined whether neurosteroid
modulation of GABARs expressed in human epilepsy is
diminished and whether there is a corresponding increase
in the expression of a4c2 subunit-containing receptors.
Furthermore, we used cultured rat hippocampal neurons
to directly evaluate the effects of increased activity on
pharmacological properties of GABARs and their subunit
composition.

Material and Methods
Human cortical brain specimens
Children with intractable epilepsy were evaluated using
standard protocols and underwent resective surgery at
Seattle Children’s Hospital. Informed consent was
obtained with the approval of the hospital’s Institutional
Review Board to use a portion of the resected tissue for
research purposes. Immediately after excision, the tissue
was frozen in liquid nitrogen and stored at 80°C. The
epileptogenic regions selected for analysis were the “most
abnormal” areas identified based on EEG, electrocorticography, imaging, and pathology data (Table 2). Age-

Figure 1. Increased expression of a4 subunit-containing GABARs in human epilepsy. (A) GABAR 4 subunit protein expression in control and
epilepsy cortical tissue. A representative blot from three control, three epilepsy-ganglioglioma, and three epilepsy-FCD IIa patients is shown. 30 lg
of protein was used for each well and b-tubulin expression was used as a loading control. Anti-a4 subunit (1:250 dilution, Novus Biologicals
NB300-194, Littleton, CO) and anti-b-tubulin (1:2000, Novus Biologicals NB600-1514) antibodies were used. (B) The expression of a4 subunits in
epilepsy tissue (336.1  42, n = 19) relative to that in control tissue (102.5  12.9, n = 10) ***P < 0.001, unpaired t-test.
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Table 2. Epilepsy brain specimens analyzed in western blotting studies.
Patient number

Age

Sex

Brain Region

Pathology

Clinical Sz. frequency

Seizure types

AED at surgery

1*
2*
3*
4*
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

7.5
8
10.8
14.2
16
5.3
6.4
8.9
9.4
3.3
5.1
18.2
4
5
6.2
6.2
8.9
6.9
13.2

F
F
M
F
M
F
F
M
F
F
F
F
M
F
M
M
M
F
M

Frontal
Temporal
Temporal
Temporal
Temporal
Occipital
Frontal
Frontal
Frontal
Frontal
Frontal
Temporal
Temporal
Temporal
Temporal
Frontal
Temporal
Temporal
Temporal

FCD 2A
FCD 2A
FCD 2A
FCD 2A
FCD 2A
FCD 2A
FCD 2B
FCD 2B
FCD 2B
TSC
TSC
TSC
GG
GG
GG
Gliosis
Gliosis
Gliosis
Gliosis

2–7/wk
4–5/day
1–4/day
1/day
1/day
10/hour
20/day
2/wk
3–10/hour
5/day
3–4/day
1–2/day
unknown
4–5/day
1–2/wk
3–5/day
1–2/month
1/day
3–4/month

FIAS
FIAS, GTC
FIAS, GTC
FIAS, GTC
FIAS, FAS
FIAS
FIAS
FIAS
GTC, FAS
FIAS, TON
FIAS
FIAS, GTC
FIAS
FIAS
FIAS
FIAS
FIAS, GTC
FIAS
FIAS, GTC

ZON, LEV
LTG, OXC, DIAZ, LRZ
ZON, LTG, CLZ
LEV, OXC, LTG
CBZ, LEV
LTG, OXC
LEV, TPM
TPM, CLR, ETHO
VPA, PHT, MDZ
LTG, ZON, LRZ
CLZ, PHB, TPM
OXC, LRZ, GBP
LTG
VPA
LEV, OXC
LTG, LEV, OXC
LTG, VPA
TPM, LTG
LTG, LEV

AED, antiepileptic drug; CBZ, carbamazepine; CLR, clorazepate; CLZ, clonazepam; DIAZ, diazepam; ETHO, ethotoin; FAS, focal aware seizures;
FIAS, focal impaired awareness seizures; FCD, focal cortical dysplasia; GBP, gabapentin; GG, ganglioglioma; GTC, generalized tonic-clonic seizures;
LEV, levetiracetam; LRZ, lorazepam; LTG, lamotrigine; MDZ, midozolam; OXC, oxcarbazepine; PHB, phenobarbital; PHT, phenytoin; TON, tonic seizures; TPM, topiramate; TSC, tuberous sclerosis complex; VPA, valproic acid; ZON, zonisamide.
*Specimens also used in electrophysiology studies.

matched, frozen, autopsy-derived, control brain tissue
(postmortem interval <15 h, non-neurologic causes of
death) was obtained from the NICHD Brain and Tissue
Bank for Developmental Disorders at the University of
Maryland, Baltimore, Maryland (Table 1). A single surgical control specimen was obtained from uninvolved tissue
that was unavoidably removed during brain tumor surgery.

Membrane isolation, Xenopus oocyte
preparation, and injection
The membranes from frozen human cortical tissue were
isolated as described previously.29 The membrane pellet
was suspended in 5 mmol/L glycine and stored frozen at
–80°C until use. The ovaries from female Xenopus laevis
were isolated and dissociated to isolate oocytes (stage V–
VI) as described previously.30 Oocytes were injected with
50–100 nL of membrane and incubated at 18°C for 1–

3 days before use. All Xenopus procedures were approved
by the Seattle Children’s Institutional Animal Care and
Use Committee (IACUC). Same membrane preparations
were used to determine GABA EC50, and allopregnanolone and Ro15-4513 modulation of GABARs.

Oocyte electrophysiology
Injected oocytes were placed in a recording chamber and
bathed in oocyte Ringer’s solution containing 82.5 mmol/
L NaCl, 2.5 mmol/L KCl, 2.5 mmol/L CaCl2, 1 mmol/L
MgCl2, and 5 mmol/L Hepes (pH 7.4). Two-electrode
voltage-clamp recordings were made at room temperature
using a GeneClamp 500B amplifier, Digidata 1322A data
acquisition system, and pCLAMP9 data analysis software
(Axon Instruments, Molecular Devices Corporation, Sunnyvale, CA).30
The absolute current amplitudes recorded in this technique of receptor “microtransplantation” are highly

Figure 2. Diminished neurosteroid modulation of GABARs in human epilepsy. (A) Potentiation of GABA-evoked currents by increasing
concentrations of allopregnanolone recorded from oocytes incorporating control and epilepsy GABARs, n = 22–26 cells expressing receptors
isolated from four control and epilepsy tissues each (*P < 0.05 vs. corresponding control, repeated measures two-way ANOVA followed by
Bonferroni post hoc analysis). At 1 lmol/L allopregnanolone, the potentiation was 730  90% in control tissue and 510  50% in epileptic
tissue, and at 3 lmol/L allopregnanolone it was 970  80% versus 660  70%. (B) Representative traces of currents evoked by GABA (10 lmol/
L) in the presence or absence of allopregnanolone (3 lmol/L) in an oocyte expressing control or epilepsy GABARs.
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variable from one oocyte to another, and are not representative of current amplitudes present in the source tissue.30,31 However, the normalized responses of these
currents to pharmacologic agents are both reflective of
that observed in the source tissue and highly reproducible.
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perfused with an external solution containing allopregnanolone (10 nmol/L) or Ro15-4513 (300 nmol/L). To
measure tonic current, the external solution was supplemented with 3 lmol/L GABA and 10 lmol/L NO711,
picrotoxin (50 lmol/L) was applied at the end of the
recordings. MiniAnalysis software (Synaptosoft) was used
to analyze mIPSCs and tonic current.34

Neuronal cultures
Rat hippocampal neuronal cultures were prepared according to a protocol approved by the University of Virginia
Animal Care and Use Committee. Dissociated hippocampal neuron-glia co-cultures were prepared from newborn
(P0) rat pups.23 Neurons plated at a density of 100 000/
35-mm culture dish and grown in vitro for 10–12 days
were used for electrophysiology and immunochemistry.
Organotypic hippocampal slice cultures prepared from
neonatal (P5-7) rat pups32 and grown in vitro for 8 days
were used for biotinylation and Western blotting experiments. The cultures were treated with 10 mmol/L KCl
(HK treatment) for 48 h, whereas control cultures were
incubated in culture medium without HK for 48 h.

Western blotting (human tissues)
Frozen cortical tissue was homogenized in 5 mmol/L
Tris/HCl (pH 7.4) with 0.32 mol/L sucrose and centrifuged at 3000g for 5 min at 4°C. The supernatant was
then centrifuged at 40,000g for 1 h at 4°C. The resultant
membrane pellet was resuspended in 5 mmol/L Tris/HCl
(pH 7.4). Standard western blotting procedures were performed to determine 4 subunit expression.33

Biotinylation and Western blotting
(hippocampal slice cultures)
Biotinylation of surface proteins and western blotting was
performed as described before.34

Cultured neuron electrophysiology
Miniature inhibitory postsynaptic GABAR-mediated currents (mIPSCs) were recorded from cultured hippocampal
pyramidal neurons using whole-cell patch clamp technique.34 After baseline recording the neurons were

Immunocytochemistry
Labeling of GABAR subunits was performed as described
before35,36 using dissociated hippocampal neurons in culture. Neurons were visualized using a Nikon Eclipse
TE200 fluorescent microscope equipped with a mercury
lamp using a 60X, 1.4 N.A. lens. Colocalization was determined using Metamorph imaging software.36

Results
Diminished neurosteroid sensitivity of
human epilepsy GABARs
Cortical brain tissue was collected from control individuals and subjects with epilepsy ranging from 1 to 20 years
in age (Control n =10, average age 9.3  2.0 years; Epilepsy n = 19, average age 8.6  1.0 years, P > 0.05,
Tables 1 and 2). GABARs in tissue removed from patients
with epilepsy are referred to as epilepsy GABARs and
those from controls as control GABARs. There was substantially higher a4 subunit expression in the tissue isolated from epilepsy patients as compared with control
cortex (Fig. 1A). The a4 level in epileptic tissue was 330%
higher than that in control tissue and was seen across
multiple pathologies, including focal cortical dysplasia
(FCD) types IIa and IIb, tuberous sclerosis complex
(TSC), ganglioglioma, and gliosis (Fig. 1B). This suggests
that enhanced a4 subunit expression may be due to
recurrent seizures rather than the underlying epilepsy etiology.
We next examined neurosteroid modulation of epilepsy
and control GABARs from a subset of the control and
epilepsy patients (n = 4 each). The epilepsy specimens
chosen for analysis all had pathologic diagnoses of FCD
IIa to increase sample homogeneity. GABA affinity of
control and epilepsy GABARs was similar (EC50

Figure 3. Enhanced modulation of GABAR currents by Ro15-4513 in human epilepsy. (A) Differential effects of Ro15-4513 on GABA (10 lmol/
L)-evoked currents in oocytes incorporating control and epilepsy GABARs; n = 26–31 cells expressing receptors isolated from four control and
epilepsy tissues each. *P < 0.05 versus corresponding control, repeated measures two-way ANOVA followed by Bonferroni post hoc analysis. (B)
Representative traces of currents evoked by GABA (10 lmol/L) in the presence or absence of Ro15-4513 (1 lmol/L) in an oocyte expressing
control or epilepsy GABARs. Ro15-4513 enhanced the current in oocytes incorporating epilepsy GABARs by 22  5%, whereas it had no effect
( 3  5%) on control GABARs.
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78.4  3.5 µmol/L vs. 63.2  2.6 µmol/L; n = 21–25
oocytes expressing receptors isolated from 4 control and
epilepsy tissues each). Allopregnanolone potentiation of
currents evoked by 10 µmol/L GABA in oocytes incorporating epilepsy GABARs was substantially attenuated compared with control GABARs (Fig. 2A). Thus, epilepsy
GABARs were less sensitive to neurosteroids than control
GABARs.
GABARs containing a4 and c2 subunits have unique
pharmacological properties, such as being insensitive to
benzodiazepines but potentiated by the compound Ro154513. Ro15-4513 is a partial inverse agonist and inhibits
the GABA-evoked currents of recombinant a1bxc2 subunit-containing receptors; however, it is a partial agonist
and potentiates the currents of recombinant a4bxc2 subunit-containing receptors.37-39 Because a4 subunit expression was increased in epilepsy GABARs, we determined
whether this resulted in distinct Ro15-4513 responses in
epilepsy and control GABARs. Application of 10 nmol/L
to 1 lmol/L Ro15-4513 did not affect GABA-evoked currents recorded from control GABARs, whereas these same
concentrations enhanced epilepsy GABAR currents
(Fig. 3).
Taken together, these data indicate increased expression
of a4c2 subunit-containing GABARs in pediatric epilepsy.
However, these studies on human tissue are unable to differentiate GABARs expressed in neuronal versus non-neuronal cells, and cannot distinguish the effects of seizures
from those of underlying pathologies and exposure to
antiepileptic medications. Therefore, in subsequent studies, we directly assessed whether increasing neuronal
activity in cultured rat hippocampal neurons results in
elevated expression of a4c2 subunit-containing GABARs
in association with altered responses to neurosteroids and
Ro15-4513.

Diminished neurosteroid modulation of
GABAR-mediated synaptic currents in High
K+ (HK)-treated neurons
Exposure of cultured rat hippocampal neurons to HK
causes membrane depolarization and increases neuronal

S. Joshi et al.

firing.23 Perturbations in neuronal activity can induce
homeostatic alterations in inhibitory and excitatory neurotransmission, which restore firing rate.19 HK-induced
increases in neuronal activity potentiate synaptic GABARmediated neurotransmission.23 However, whether this
plasticity results from upregulation of existing receptors
or from synthesis of different receptor isoforms was not
evaluated. We first determined whether GABARs with
altered neurosteroid sensitivity were expressed in HKtreated neurons.
Allopregnanolone was less effective in potentiating
GABAR-mediated synaptic transmission in HK-treated
neurons compared to control neurons (Fig. 4A and B).
Larger amplitude mIPSCs were recorded from the neurons exposed to HK for 2 days indicating homeostatic
plasticity; however, allopregnanolone (10 nmol/L) was
less effective in prolonging mIPSC decay in these neurons compared untreated controls. Allopregnanolone did
not affect the frequency, amplitude, or 10–90% rise-time
of mIPSCs in control or HK-treated neurons (Table 3),
consistent with previous studies, which have found that
allopregnanolone at lower doses prolongs the decay and
at higher doses increases the amplitude of the current.14,40
We then determined allopregnanolone modulation of
tonic GABAR currents in HK-treated neurons. In contrast
to potentiation of synaptic currents, HK treatment did
not affect allopregnanolone modulation of total tonic current. Allopregnanolone increased the tonic current of
control and HK-treated neurons in a similar manner
(Fig. 4C). Thus, the neurosteroid potentiation of tonic
GABAR currents was preserved in HK-treated neurons.

HK treatment alters GABAR isoforms
Altered synaptic GABAR subunit composition can explain
the observed diminution in neurosteroid sensitivity of
synaptic currents in HK-treated neurons. The diminished
neurosteroid sensitivity of GABAergic synaptic neurotransmission of DGCs from animals with epilepsy is associated with increased expression of a4c2 subunitcontaining GABARs.13,15,18 Since receptors expressed on

Figure 4. Reduced neurosteroid modulation of synaptic currents in HK-treated neurons. (A) Representative voltage clamp recordings showing the
effect of allopregnanolone (10 nmol/L) in cultured dissociated hippocampal neurons either untreated or treated with HK (10 mmol/L, 48 h). (B)
Averaged current from representative control and HK-treated neurons before (black) and after application of allopregnanolone (gray). Bath
application of allopregnanolone (10 nmol/L) prolonged the decay from 35  2 msec to 43  3 msec (n = 13, P < 0.0005, paired t-test) in
control cultures. In contrast, the decay was only prolonged from 29  2 msec to 34  2 msec in the HK-treated neurons (n = 12, P < 0.005,
paired t-test). All values are presented as mean  SEM. (C) The allopregnanolone modulation of tonic current in HK-treated and control neurons.
The arrows represent the start of bath application of allopregnanolone (10 nmol/L) and picrotoxin (50 lmol/L). Total tonic current in HK-treated
and control cultures was 25  4 pA, n = 5 and 28  3 pA, n = 6 neurons, P > 0.05. Allopregnanolone enhanced the tonic current by
26  5 pA in HK-treated neurons (n = 14), similar to that in control neurons, 24  3 pA, n = 12, P > 0.05, t-test.

534

ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

S. Joshi et al.

GABAR Plasticity in Human Epilepsy

ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

535

GABAR Plasticity in Human Epilepsy

S. Joshi et al.

Table 3. Miniature inhibitory postsynaptic currents recorded from HK-treated (10 mM KCl, 48 h) or untreated neurons by allopregnanolone
(10 nmol/L, allo) or Ro15-4513 (300 nmol/L, Ro).

Amplitude (pA)

Control (n = 13)
HK (n = 12)
Control (n = 6)
HK (n = 7)

Frequency (Hz)

10–90% rise time (msec)

Weighted decay
(msec)

Pre-allo

Post-allo

Pre-allo

Post-allo

Pre-allo

Post-allo

Pre-allo

Post-allo

53  1
64  4*
Pre-Ro
50  3
69  6*

55  3
63  4
Post-Ro
53  3
66  4

0.26  0.06
0.42  0.06
Pre-Ro
0.23  0.06
0.31  0.1

0.23  0.06
0.39  0.07
Post-Ro
0.27  0.07
0.23  0.06

2.3  0.2
2.0  0.2
Pre-Ro
2.3  0.1
2.3  0.08

2.3  0.3
1.6  0.1
Post-Ro
2.2  0.2
2.3  0.09

35  2
29  2*
Pre-Ro
42  5
40  4

43  3†
34  2†
Post-Ro
37  5†
42  6

*P < 0.05 versus control (t-test).
†
P < 0.05 versus predrug (paired t-test).

the cell surface regulate the pharmacological properties of
GABARs, we determined whether the surface expression
of GABAR subunits was altered following HK treatment
using a biotinylation assay. Higher amounts of c2 and a4
subunits were expressed on the neuronal surface membrane in HK-treated cultures compared to controls. Furthermore, total c2 subunit protein expression was higher
in HK-treated hippocampal slice cultures compared to
control cultures, whereas that of the a4 subunits was not
significantly changed (Fig. 5A). In contrast, surface and
total expression of the subunit in HK-treated and control
cultures was similar (Fig. 5A and B).
Increased surface expression of a4 and c2 GABAR subunits suggested potential changes in subunit assembly. To
determine whether there was increased synaptic targeting
of a4c2 subunit-containing GABARs, we colocalized a4
and c2 subunit immunoreactivity on cell membranes of
cultured hippocampal neurons. The punctate c2 subunit
immunoreactivity was distributed over the soma and dendrites in the control and HK-treated cultures (Fig. 6A).
The a4 subunit immunoreactvity was diffusely distributed
over cell soma and dendrites of control neurons and only
a few clusters were observed (Fig. 6A). In contrast, in
HK-treated cultures the a4 subunit immunoreactivity was

punctate. In the HK-treated cultures the c2 and a4 subunit immunoreactivity was higher, and the degree of
colocalization was also greater than that in controls
(Fig. 6A and D).

Alterations in the effect of Ro15-4513 in
cultured neurons
The immunochemical studies suggested that a4c2 subunit-containing GABARs were assembled in HK-treated
neurons. We directly tested this by determining the effect
of Ro15-4513 on mIPSCs. Ro15-4513 (300 nmol/L) was
bath applied and it shortened the decay of mIPSCs in
control neurons, consistent with expression of a1bxc2
subunit-containing receptors (Fig. 6E, Table 3). In contrast, Ro15-4513 did not affect the mIPSC decay in HKtreated neurons (Fig. 6E, Table 3).
We also tested whether a4bxc2 subunit-containing
receptors were present at the extrasynaptic membrane.
Ro15-4513 modulation of tonic current was greater in
HK-treated neurons (20  4 pA, n = 6, P = 0.0004)
compared to that in control neurons (5  1 pA, n = 10),
indicating that some of the a4bxc2 subunit-containing
receptors were also present at the extrasynaptic sites.

Figure 5. Increased surface expression of c2 and a4 subunits in HK-treated cultures. (A) Representative western blots showing the surface and
total expression of the c2, a4, and d subunits in HK-treated (HK) and control (C) organotypic hippocampal slice cultures. The expression of b-actin
is shown to demonstrate the purity of the surface samples. Mouse monoclonal anti-c2 subunit antibody 10F10-C1-B8 (2 lg/mL dilution),49 rabbit
polyclonal anti-a4 subunit antibody (1:400 dilution, Millipore, Billerica, MA), anti- subunit antibody (1:1000, Millipore, Billerica, MA), and anti-bactin (1:5000, clone AC-40, Sigma-Aldrich) were used. Lane M shows molecular weight marker. (B) Total (T) and surface (S) expression of c2, a4,
and d subunits in HK-treated slice cultures. Data represent average and standard error from n = 11 for c2 subunits, n = 6 for d subunits and
n = 4 for a4 subunits, *P < 0.05. The subunit protein expression in HK-treated cultures was normalized to that in control cultures which were run
in parallel in every experiment. The total c2 subunit expression in HK-treated cultures was 179  25% of that in control cultures (P < 0.05,
Mann–Whitney test), the d subunit expression was 91  10% of that in controls (P > 0.05), and that of the a4 subunit was 139  56% of that
in controls (P > 0.05). The normalized surface expression (S) of c2 subunits with HK treatment was 153  11% of that in controls (P < 0.05,
Mann–Whitney test, Fig. 4B), the a4 subunit surface expression in HK-treated neurons was 158  7%, P < 0.05, and the d surface expression of
the subunit in HK-treated neurons was 121  16%, P > 0.05.
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Figure 6. HK treatment increased co-localization between c2 and a4 subunits. (A) Images demonstrating surface immunoreactivity of the c2
(green) and a4 (red) subunits and their colocalization over dendrites of representative control and HK-treated neurons. Arrows mark colocalization
of the immunoreactive puncta. (B and C) Number of pixels corresponding to the c2 and a4 subunit immunoreactivity in control and HK-treated
neurons, respectively, n = 16 control neurons from four batches of cultures and n = 26 HK-treated neurons from 4 batches of cultures,
*P < 0.05, **P < 0.005. The average number of c2 puncta per neuron in controls was 338  84 (n = 16 neurons from 4 replicate cultures), and
in HK-treated neurons it was 654  76 (n = 26 from 4 replicate cultures, P < 0.005, t-test). The number of a4 subunit puncta was also higher
with 170  14 in HK-treated neurons compared to 97  9 in control neurons (P < 0.05). (D) The number of pixels at which the c2 and a4
subunit immunoreactivities colocalized, the number of replicates is identical as that in panel B and C, *P < 0.05. The average number of
colocalized puncta was 146  13 in control neurons and 395  71 in HK-treated neurons. (E) Averaged currents illustrating the effect of Ro154513 (300 nmol/L, grey trace) on mIPSCs recorded from a representative control and HK-treated neuron. The black trace illustrates current before
the application of Ro15-4513. In the control neurons decay shortened from 42  5 msec to 37  5 msec (n = 6 neurons/6 replicate cultures,
P < 0.05, paired t-test), whereas it remained stable in HK-treated neurons (40  4 msec and 42  6 msec, n = 7 neurons/6 replicate cultures,
P > 0.05, paired t-test). The average change in decay was 5.6  1.5 msec in control neurons and 1.7  1.1 msec in HK-treated neurons
(P < 0.05).

Discussion
The major findings of this study are (1) GABARs with
diminished neurosteroid sensitivity are expressed in cortical tissue isolated from human epilepsy patients, (2)
Ro15-4513 potentiates currents recorded from GABARs
expressed in human epilepsy, (3) a4 subunit expression is
higher in tissue of epilepsy patients than in control tissue,
(4) increased neuronal activity triggered by HK treatment
upregulates the expression of a4c2 subunit-containing
receptors in cultured hippocampal neurons, and (5) HKinduced neuronal activity diminishes the neurosteroid
potentiation of synaptic GABAR-mediated currents.
Our study demonstrates the expression of GABARs
with diminished neurosteroid sensitivity in human epilepsy. This alteration likely renders neurons less protected
from seizures. Neurosteroid regulation of GABAR-mediated inhibition plays a critical role in controlling neuronal
activity and keeping seizures under control.41 Decreased
allopregnanolone levels concomitant with reduced progesterone levels towards the end the menstrual cycle are
linked to perimenstrual seizure exacerbation in women
with epilepsy.42,43 X-linked epilepsy in PCDH19 patients
is also associated with reduced neurosteroid production.44
This study performed using tissue from pediatric patients
found expression of GABARs with reduced neurosteroid
sensitivity. These alterations are likely to impact the anticonvulsant activity of progesterone and could contribute
to catamenial seizure exacerbation after menarche in
female patients. The pharmacological properties of
GABARs expressed in cortical tissue of epilepsy patients
were also similar to those composed of a4c2 subunits.
These findings complement studies in experimental animals in which increased expression of a4c2 subunit-containing receptors is associated with diminished
neurosteroid and diazepam modulation of GABAR currents in DGCs from animals with temporal lobe epilepsy.12-15,18,45,46

These findings are important for treatment considerations. In a recently concluded trial of catamenial epilepsy,
progesterone—which exerts anticonvulsant effects via
conversion to neurosteroids—was not efficacious in suppressing seizures in women with epilepsy.47 The synthetic
neurosteroid ganaxolone also has limited therapeutic efficacy for treatment of epilepsy.48 The expression of receptors with reduced neurosteroid sensitivity in epilepsy
could result in refractoriness to these drugs. However, at
the same time, the increased expression of a4c2 subunitcontaining GABARs may provide a novel target for treatment. For example, flumazenil, a benzodiazepine-site
ligand with similar pharmacology to Ro15-4513,37 reduces
interictal epileptiform activity in patients with intractable
epilepsy,49 although its concomitant blockade of conventional benzodiazepine-sensitive GABARs limits its clinical
utility.
Several studies have found increased a4 subunit expression, accompanied by diminished neurosteroid and diazepam sensitivity, and increased zinc and Ro15-4513
sensitivity of GABARs in experimental animals with epilepsy.13-15,18,45-46,50 However, whether the GABARs
expressed in human epilepsy have pharmacological properties similar to those reported in experimental animals
was unclear. We found markedly increased a4 GABAR
subunit expression in tissue isolated from patients with
intractable epilepsy and pharmacological alterations similar to those found in epileptic animals. Other human epilepsy tissue studies have also identified either an absolute
increase in a4 GABAR subunit protein or mRNA expression, or an increase in the a4 to a1 subunit ratio.51-53 Our
previous work has indicated that other epilepsy-associated
alterations in GABAR subunit expression are pathologydependent;33 however, the consistent upregulation of a4
expression in epilepsy across multiple pathologies suggests
that this change may be driven by the increased neuronal
activity that occurs during seizures instead of an effect of
the underlying etiology of the seizures.
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Homeostatic plasticity, strengthening or weakening of
synapses, occurs in response to changes in network activity.19-22,54 Increased firing of cultured hippocampal neurons due to depolarization induced by HK potentiates
synaptic GABAergic currents.23 We found that exposure
to HK caused upregulation of a4c2 subunit-containing
receptors, likely as a homeostatic response. However, this
appears to be an imperfect response, as the pharmacological properties of the receptors were distinct from those
expressed in untreated neurons. Low neurosteroid sensitivity of the receptors expressed in HK-exposed neurons
would limit their effectiveness in controlling neuronal
excitability.
Ro15-4513 shortened the decay of mIPSCs recorded
from control cultured neurons, whereas it did not affect
decay in HK-treated neurons. These findings agree with
the predominant expression of a1c2 subunit-containing
receptors in control cultures,36 where Ro15-4513 would
be expected to act as a partial inverse agonist, versus a
relative increase in a4c2 receptors in HK-treated cultures,
where Ro15-4513 would be expected to act as a partial
agonist. The inhibitory effect of Ro15-4513 on a1c2 subunit-containing receptors was likely counterbalanced by
the potentiation of newly expressed a4c2 subunit-containing receptors in HK-treated neurons. Furthermore, a
greater modulation of tonic current of HK-treated neurons by Ro15-4513 suggests that some of the a4c2 receptors were present at the extrasynaptic membrane.
Similarly, Ro15-4513 had differential actions on GABARs
from control versus epilepsy patients, increasing the
amplitude of GABA currents mediated by receptors
expressed in human epilepsy while having no effect on
control receptors. Ro15-4513 also prolongs the decay of
mIPSCs recorded from DGCs of epileptic animals14 and
causes a greater modulation of tonic current of DGCs of
epileptic animals compared to that in control DGCs.13
In contrast to synaptic currents, neurosteroid modulation of tonic current was unaffected and the subunit
expression was also unchanged in HK-treated neurons.
The d and a4 subunits have distinct pharmacological
properties.55 The neurosteroid modulation of tonic current is mainly dependent on subunit-containing receptors,56 whereas the effect of Ro15-4513 is dependent on
a4c2 subunit-containing receptors. The observed effects
of allopregnanolone and Ro15-4513 on tonic current of
HK-treated neurons are in agreement with preserved subunit and upregulated a4c2 subunit expression. Based on
these findings, the subunit-containing GABARs do not
appear to contribute to homeostatic plasticity. Studies in
experimental animals also suggest that distinct mechanisms regulate the plasticity of d, a4, and c2 subunits.18,26
HK treatment replicated pharmacological alterations
seen in epilepsy patients, but, there appear to be some
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distinctions in the underlying mechanisms. Total a4 subunit expression was increased in the tissue isolated from
patients, whereas surface expression but not the total
expression of this subunit was upregulated in HK-treated
neurons. It is possible that a longer exposure of cultures
to HK conditions may also upregulate the total subunit
expression. Exposure to antiepileptic drugs may also have
effects on the tissue isolated from patients.
In conclusion, this study revealed the expression of
GABARs with diminished neurosteroid sensitivity and
altered Ro15-4513 modulation in both human epileptic
cortex and chronically depolarized neurons in vitro. These
findings indicate that increasing neuronal activity via
either recurrent seizures or pharmacologic depolarization
triggers plasticity of GABARs, leading to higher expression of receptors containing a combination of a4 and c2
subunits. This plasticity may impair the anticonvulsant
actions of endogenous and exogenous neurosteroids, but
it may also suggest avenues for development of new antiseizure medications.
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